Business Context and Reporting Period
This Form 8-K Current Report was filed by Oragenics, Inc. on May 2, 2006, covering events occurring on that date and effective May 5, 2006. The company is a Florida-based biotechnology firm focused on proprietary Differentially Protected Orthogonal Lanthionine Technology (DPOLT).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes and a specific grant award rather than financial performance data.
Material Changes
- Board Departure: Brian Anderson ceased serving as a Director effective May 5, 2006, due to personal reasons and a decision not to stand for re-election.
- Executive Resignation: Paul A. Hassie resigned as Chief Financial Officer, Secretary, and Treasurer effective May 5, 2006, citing personal reasons. The company has initiated a search for his successor.
- Grant Award: The company was awarded an SBIR Phase 1 grant from the National Science Foundation (NSF) for lantibiotic synthesis using its DPOLT technology.
Outlook, Risks, and Management Commentary
Management confirmed that the departures of Mr. Anderson and Mr. Hassie were not related to any disagreement or dispute with the Company's management. The award of the NSF grant indicates continued progress in the company's research and development initiatives regarding lantibiotic synthesis. No specific financial guidance or risk factors were detailed in this filing.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer to replace Paul A. Hassie.
- Confirm the specific dollar amount and terms of the NSF SBIR Phase 1 grant.
- Review subsequent filings for any updates on the Board of Directors composition following Brian Anderson's departure.